Article
Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.
American journal of respiratory and critical care medicine - 15 Jan 2014
Blackwell Timothy S, Tager Andrew M, Borok Zea, Moore Bethany B, Schwartz David A, Anstrom Kevin J, Bar-Joseph Ziv, Bitterman Peter, Blackburn Michael R, Bradford William, Brown Kevin K, Chapman Harold A, Collard Harold R, Cosgrove Gregory P, Deterding Robin, Doyle Ramona, Flaherty Kevin R, Garcia Christine Kim, Hagood James S, Henke Craig A, Herzog Erica, Hogaboam Cory M, Horowitz Jeffrey C, King Talmadge E, Loyd James E, Lawson William E, Marsh Clay B, Noble Paul W, Noth Imre, Sheppard Dean, Olsson Julie, Ortiz Luis A, O'Riordan Thomas G, Oury Tim D, Raghu Ganesh, Roman Jesse, Sime Patricia J, Sisson Thomas H, Tschumperlin Daniel, Violette Shelia M, Weaver Timothy E, Wells Rebecca G, White Eric S, Kaminski Naftali, Martinez Fernando J, Wynn Thomas A, Thannickal Victor J, Eu Jerry P
Abstract excerpt
The median survival of patients with idiopathic pulmonary fibrosis (IPF) continues to be approximately 3 years from the time of diagnosis, underscoring the lack of effective medical therapies for this disease. In the United States alone, approximately 40,000 patients die of this disease annually. In November 2012, the NHLBI held a workshop aimed at coordinating research efforts and accelerating the development of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.